Pfizer and Allergan terminated their $150 billion proposed merger after the Obama Administration took aim at corporate inversion deals. WSJ's Liz Hoffman joins Lunch Break with Tanya Rivero and explains how the termination potentially affects future corporate mergers. Photo: Reuters
